Glutarimide, N-allyl-3-phenyl- | 10259-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Glutarimide, N-allyl-3-phenyl-
• 英文别名: 4-phenyl-1-prop-2-enylpiperidine-2,6-dione
• CAS: 10259-37-7
• 化学式: C₁₄H₁₅NO₂
• 分子量: 229.27
• InChiKey: MABRYOARRDHTFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
  申请人：CELGENE CORPORATION

  公开号：EP1676577A1

  公开（公告）日：2006-07-05

  This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment orprevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

  本发明涉及由沙利度胺和另一种可用于治疗或预防癌症的抗癌药物组成的组合物。首选的抗癌药物是拓扑异构酶抑制剂。一种特殊的组合物包含沙利度胺或其药学上可接受的盐、溶液或凝胶，以及伊立替康。本发明还涉及治疗或预防癌症的方法，其中包括向需要这种治疗或预防的病人施用沙利度胺和另一种抗癌药物。本发明还涉及减少或避免与化疗或放疗相关的不良副作用的方法，其中包括向需要减少或避免不良副作用的患者施用沙利度胺。
• Compositions and methods for the treatment of cancer
  申请人：——

  公开号：US20020035090A1

  公开（公告）日：2002-03-21

  This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

  本发明涉及由沙利度胺和另一种可用于治疗或预防癌症的抗癌药物组成的组合物。首选的抗癌药物是拓扑异构酶抑制剂。一种特定的组合物包含沙利度胺或其药学上可接受的盐、溶液或凝胶，以及伊立替康。本发明还涉及治疗或预防癌症的方法，其中包括向需要治疗或预防癌症的患者施用沙利度胺和另一种抗癌药物。本发明还涉及减少或避免与化疗或放疗相关的不良副作用的方法，其中包括向需要减少或避免不良副作用的患者施用沙利度胺。
• Compositions and methods for the treatment of colorectal cancer
  申请人：——

  公开号：US20020035091A1

  公开（公告）日：2002-03-21

  This invention relates to compositions comprising thalidomide and irinotecan, which can be used in the treatment or prevention of colorectal cancer. The invention also relates to methods of treating or preventing colorectal cancer which comprise the administration of thalidomide and irinotecan to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of irinotecan which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

  本发明涉及包含沙利度胺和伊立替康的组合物，可用于治疗或预防结直肠癌。本发明还涉及治疗或预防结直肠癌的方法，其中包括向需要这种治疗或预防的患者施用沙利度胺和伊立替康。本发明进一步涉及减少或避免与服用伊立替康相关的不良副作用的方法，其中包括向需要减少或避免不良副作用的患者服用沙利度胺。
• Methods of using thalidomide in combination with irinotecan
  申请人：Govindarajan Rangaswamy

  公开号：US20050203060A1

  公开（公告）日：2005-09-15

  This invention relates to compositions comprising thalidomide and irinotecan, which can be used in the treatment or prevention of colorectal cancer. The invention also relates to methods of treating or preventing colorectal cancer which comprise the administration of thalidomide and irinotecan to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of irinotecan which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

  本发明涉及包含沙利度胺和伊立替康的组合物，可用于治疗或预防结直肠癌。本发明还涉及治疗或预防结直肠癌的方法，其中包括向需要这种治疗或预防的患者施用沙利度胺和伊立替康。本发明进一步涉及减少或避免与服用伊立替康相关的不良副作用的方法，其中包括向需要减少或避免不良副作用的患者服用沙利度胺。
• COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER COMPRISING THALIDOMIDE AND IRINOTECAN
  申请人：CELGENE CORPORATION

  公开号：EP1286671B1

  公开（公告）日：2006-04-05